
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
GILD | NASDAQ | USD | Real-time | |
GILD | Mexico | MXN | Delayed | |
GGILD | Milan | EUR | Real-time | |
GILD | Xetra | EUR | Delayed | |
GILD | Frankfurt | EUR | Delayed | |
GILD | TradeGate | EUR | Delayed | |
GILD | Santiago | USD | Delayed | |
GILDCL | Santiago | CLP | Delayed | |
GILD | Buenos Aires | ARS | Delayed | |
GILD | Vienna | EUR | Delayed |
Gilead Sciences, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicine to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company’s products for HIV/AIDS patients include Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. Its COVID-19 product is Veklury. The products for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. The products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy, and Zydelig. The other products include Letairis (ambrisentan), Ranexa (ranolazine), Cayston, Jyseleca, and AmBisome (amphotericin B liposome for injection). The Company also sells and distributes generic versions of Epclusa and Harvoni in the United States. The Company is also focused on restoring immune balance with agonists targeting immune inhibitory receptors.
Name | Age | Since | Title |
---|---|---|---|
Eugene R. Schiff | - | - | Member of the Scientific Advisory Board |
Jacqueline K. Barton | 68 | 1989 | Independent Director |
Paul E. Klotman | - | - | Member of the Scientific Advisory Board |
John W. Mellors | 83 | - | Member of the Scientific Advisory Board |
Francis V. Chisari | - | - | Member of the Scientific Advisory Board |
Sandra J. Horning | 72 | 2020 | Independent Director |
Mark C. Genovese | - | - | Member of Scientific Advisory Board |
Daniel P. O'Day | 57 | 2019 | Chairman & CEO |
Harish M. Manwani | 68 | 2018 | Independent Director |
Malcolm MacCoss | 73 | - | Member of Scientific Advisory Board |
Nezam H. Afdhal | 64 | - | Member of Scientific Advisory Board |
Robert A. Harrington | - | - | Member of the Scientific Advisory Board |
Kevin E. Lofton | 66 | 2009 | Lead Independent Director |
Paul Berg | 94 | 1998 | Member of Scientific Advisory Board |
Kelly A. Kramer | 53 | 2016 | Independent Director |
Eric J. Topol | 67 | - | Member of Scientific Advisory Board |
Robert T. Schooley | - | - | Member of the Scientific Advisory Board |
Kenneth C. Anderson | 70 | - | Member of the Scientific Advisory Board |
Brian J. Druker | 66 | - | Member of the Scientific Advisory Board |
Joel R. Huff | - | - | Chairperson of Scientific Advisory Board |
Javier J. Rodriguez | 50 | 2020 | Independent Director |
Jeffrey A. Bluestone | 68 | 2020 | Independent Director |
Anthony Welters | 66 | 2020 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review